SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma to invest $200 million on Capex in FY20

17 Jun 2019 Evaluate

Aurobindo Pharma is eyeing to invest up to $200 million on Capex and over five percent of sale value on Research and Development (R&D) during the current financial year. The majority of the CAPEX should be in terms of creating certain both finished dosage and API capacities.

The company had spent $225 million on capex last year and R&D expenditure was at Rs 872 crore or 4.5 percent of the revenues for the year.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1379.30 -6.35 (-0.46%)
20-Apr-2026 11:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.90
Dr. Reddys Lab 1237.60
Cipla 1237.10
Zydus Lifesciences 941.00
Lupin 2328.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×